Results 91 to 100 of about 9,912 (208)

Ten Years of Vildagliptin [PDF]

European Endocrinology, 2017
After many years of limited therapeutic opportunities, the treatment of type 2 diabetes has become more target and pathophysiologically driven. A typical example is represented by the development of the dipeptidyl peptidase-4 (DPP-4) inhibitors, allowing for more physiological regulation of the endocrine pancreas and leading to a previously unmet risk ...
openaire   +2 more sources

Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases [PDF]

, 2016
Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Due to their promising action on insulinotropic secretion and improving insulin resistance (IR), incretin-based therapies have become a new ...
Holscher, Christian, Li, Lin, Li, Yanwei
core   +1 more source

Sita‐ and saxagliptin use and autoantibodies to autoimmune bullous diseases: A cross‐sectional study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page e227-e230, April 2026.
Sören Dräger, Claudia Kauderer, Svenja Meyhöfer, Leonie Dräger, Jens U. Marquardt, Ralf J. Ludwig, Stephan Arndt, Katharina Boch, Katja Bieber   +8 more
wiley   +1 more source

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly [PDF]

, 2016
PURPOSE: Cushing’s disease (CD) and acromegaly are characterized by excessive hormone secretion resulting in comorbidities such as impaired glucose metabolism, diabetes and hypertension.
Silverstein, Julie M
core   +2 more sources

Effectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus: Real-World Evidence in Indian Patients [NOVELTY Study]

Drugs - Real World Outcomes
Background and Objective Vildagliptin sustained release (XR), a formulation that provides vildagliptin 100 mg with a once-daily dose administration, is a recent introduction to manage type 2 diabetes mellitus in India.
Rakesh Sahay, Anil Bhansali, Surendra Kumar Sharma, Rahul Iyer, Amarnath Sugumaran, Senthilnathan Mohanasundaram, Jaideep Gogtay   +6 more
doaj   +1 more source

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

Drug Design, Development and Therapy, 2014
Mustafa Cakirca,1 Cumali Karatoprak,1 Mehmet Zorlu,1 Muharrem Kiskac,1 Mustafa Kanat,2 Mehmet Ali Cikrikcioglu,1 Pinar Soysal,3 Mehmet Hursitoglu,4 Ahmet Adil Camli,1 Reha Erkoc,1 Muhammad Abdul-Ghani5 1Internal Medicine Clinic, Faculty of Medicine ...
Cakirca M, Karatoprak C, Zorlu M, Kiskac M, Kanat M, Cikrikcioglu MA, Soysal P, Hursitoglu M, Camli AA, Erkoc R, Abdul-Ghani M   +10 more
doaj  

Comparative Effectiveness and Safety of Acarbose and Vildagliptin in Type 2 Diabetes Management: A Real-World Observational Study in an Indian Population

Clinical Diabetology
OBJECTIVE: To evaluate and compare the real-world effectiveness and safety profiles of Acarbose and Vildagliptin in patients with type 2 diabetes (T2D), with an additional focus on their impacts on the gut microbiota.
Shambo Samrat Samajdar, Shatavisa Mukherjee, Rutul Gokalani, Supratik Bhattacharyya, Banshi Saboo, Shashank Joshi   +5 more
doaj   +1 more source

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study

Diabetes, Metabolic Syndrome and Obesity, 2016
Ahmed AK Hassoun,1 Md Faruque Pathan,2 Rita C Medlej,3,4 Monira Alarouj,5 Inass Shaltout,6 Manoj S Chawla,7 Ditte Knap,8 Julius A Vaz9 1Dubai Diabetes Centre, Dubai, UAE; 2Department of Endocrinology, BIRDEM Hospital, Dhaka, Bangladesh; 3Department of ...
Hassoun AAK, Pathan MF, Medlej RC, Alarouj M, Shaltout I, Chawla MS, Knap D, Vaz JA   +7 more
doaj  

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

Vascular Health and Risk Management, 2008
Nasser MikhailEndocrinology Division, Olive View-UCLA Medical Center, David-Geffen School of Medicine, CA, USAAbstract: Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the action of incretin hormones through ...
Nasser Mikhail
doaj  

Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting [PDF]

, 2015

core   +1 more source